By Measuring The Effect On A Living Organism, Tissue, Or Cell Patents (Class 506/10)
-
Publication number: 20140331341Abstract: The present invention relates to methods and compositions for high content drug screening in C. elegans which may be used to identify compounds that treat disorders associated with protein aggregation.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EdUcationInventors: Stephen C. Pak, David H. Perlmutter, Gary A. Silverman
-
Publication number: 20140329716Abstract: The disclosure relates to devices, systems and methods that address the variability in immunohistochemistry (IHC) tests that can lead to inaccurate diagnosis or misdiagnosis while maintaining important structural information within the specimen. The devices may include a control region having a control unit including a plurality of substantially homogenous samples and a biological sample region.Type: ApplicationFiled: August 28, 2012Publication date: November 6, 2014Applicant: EMORY UNIVERSITYInventors: Brad A. Kairdolf, Shuming Nie
-
Publication number: 20140329718Abstract: The invention relates to a genetically encoded fluorescent sensor for nicotinamide adenine dinucleotide, as well as methods of preparation and uses thereof. In one aspect, this invention relates to a sensor for detecting nicotinamide adenine dinucleotide, particularly, a recombinant fluorescent fusion protein sensor for detecting nicotinamide adenine dinucleotide. In one specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting reduced nicotinamide adenine dinucleotide (NADH); in another specific aspect, this invention relates to a recombinant fluorescent fusion protein sensor for detecting oxidized nicotinamide adenine dinucleotide (NAD+); in yet another aspect, the invention relates to a recombinant fluorescent fusion protein sensor for detecting the ratio of reduced to oxidized nicotinamide adenine dinucleotide.Type: ApplicationFiled: September 26, 2012Publication date: November 6, 2014Applicant: East China University of Science and TechnologyInventors: Yi Yang, Jing Jin, Yuzheng Zhao, Qingxun Hu
-
Publication number: 20140323351Abstract: The present invention relates to single cell array micro-chips and fabrication, electrical measurement and electroporation method thereof. The single cell array microchip comprises a substrate (1), a plurality of positioning electrodes (2) formed in an array, a plurality of measuring electrode-pairs (3) formed in an array, and a micro sample pool (4). The invention integrates cell array positioning with electrical measurement and electroporation for living cells, which is characteristic of label-free and noninvasive methods to manipulate, position particles/cells as well as further measure their electrical parameters. Therefore, single-cell-array positioning and multi-mode in-situ real-time measurement can be realized for intensive analysis. Since the positioned cells are immobile, the precision of the electrical measurement of cells is effectively improved, so is the efficiency of electroporation with lower cell mortality rate.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: Rong ZHU, Xiaoliang GUO
-
Publication number: 20140323406Abstract: The invention provides methods of treating stroke and related conditions exacerbated by fever and/or hyperglycemi by administering peptides or peptidomimetics that inhibit binding of NMDAR 2B to PSD-95 to a patient.Type: ApplicationFiled: February 7, 2014Publication date: October 30, 2014Applicant: NONO INC.Inventor: Michael Tymianksi
-
Publication number: 20140322188Abstract: The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis.Type: ApplicationFiled: April 26, 2013Publication date: October 30, 2014Applicant: ENZO BIOCHEM, INC.Inventors: RICHARD NUSSENBLATT, BAOYING LIU, LAI WEI, ELAZAR RABBANI, JAMES J. DONEGAN
-
Publication number: 20140323340Abstract: The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials.Type: ApplicationFiled: July 11, 2014Publication date: October 30, 2014Inventors: David A. Goldberg, David C. Howson, Steven W. Metzger, Daniel A. Buttry, Steven Scott Saavedra
-
Publication number: 20140314791Abstract: The present invention provides methods of treating cancer, particularly cancers that are null or have decreased expression or activity of the Lkb1 gene. Also included are methods of identifying therapeutic targets for the treatment of cancer.Type: ApplicationFiled: January 4, 2013Publication date: October 23, 2014Inventors: Kwok-Kin Wong, Yan Liu
-
Publication number: 20140315753Abstract: Aspects of the present disclosure are directed to methods and compositions for the production of heterogeneous tissue from human induced pluripotent stem (hiPS) cells.Type: ApplicationFiled: March 18, 2014Publication date: October 23, 2014Applicant: Massachusetts Institute of TechnologyInventors: Patrick Guye, Ron Weiss
-
Publication number: 20140315754Abstract: Embodiments are directed to methods and compositions for determining the level of DCLK1-S in a sample and treating a subject having elevated levels of DCLK1-S.Type: ApplicationFiled: April 5, 2014Publication date: October 23, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Pomila Singh, Shubhashish Sarkar, Malaney O'Connell
-
Publication number: 20140314723Abstract: The disclosure relates to cell culture vessels comprising fabricated cell culture surfaces providing means for efficient corneal endothelial cell growth and the use of the cultured cells in the repair of corneal tissue damage.Type: ApplicationFiled: April 17, 2014Publication date: October 23, 2014Applicant: National University of SingaporeInventors: King Fai Evelyn Yim, Kim Kiat Teo, Stephanie Koo
-
Patent number: 8865629Abstract: The invention relates to techniques for the rapid screening of suitable translational fusion partners (TFPs) capable of inducing secretory production of recombinant proteins, especially proteins that are difficult to produce using conventional recombinant production methods.Type: GrantFiled: July 13, 2006Date of Patent: October 21, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Jung-Hoon Sohn, Eui-Sung Choi, Jung-Hoon Bae, Mi-Kyung Shin, Sung-Sook Yoon, Chang-Soo Chun
-
Patent number: 8865630Abstract: High throughput system for in vivo screens on vertebrate larvae. The system includes a source of vertebrate larvae in a liquid medium and loading tube means for aspirating a larva. A detector assembly is provided to differentiate passage of a larva from bubbles and/or debris. An imaging means is provided for both confocal imaging and wide-field fluorescence imaging of the larva. A laser is provided for optical manipulation of the larva.Type: GrantFiled: February 26, 2010Date of Patent: October 21, 2014Assignee: Massachusetts Institute of TechnologyInventors: Mehmet F. Yanik, Steven C. Wasserman, Carlos Pardo, Cody L. Gilleland, Tsung-Yao Chang
-
Publication number: 20140309135Abstract: A method of screening a compound having a hypoglycemic effect (hereinafter referred to as “hypoglycemic compound”), a remedy for diabetes which contains a compound having a novel function mechanism, etc. More specifically speaking, a method of screening a hypoglycemic compound capable of binding to the ? subunit of a trimeric GTP-binding protein, a remedy for diabetes comprising a hypoglycemic compound, which is characterized by being capable of binding to the ? subunit of a trimeric GTP-binding protein, as the active ingredient, etc.Type: ApplicationFiled: April 25, 2014Publication date: October 16, 2014Applicant: AJINOMOTO CO., INC.Inventors: Naoyuki FUKUCHI, Satoru Okamoto, Wataru Miyanaga, Sen Takeshita, Masaru Takayanagi, Yumiko Fukuda, Takao Ikenoue, Naoyuki Yamada, Naoko Arashida
-
Publication number: 20140303036Abstract: The present invention relates to a method for the preparation of a library of host cells, a plurality of which comprise an assembled polynucleotide at a target locus, which method comprises: (a) providing a plurality of polynucleotides comprising two or more polynucleotide subgroups, wherein: (i) a plurality of polynucleotides in each polynucleotide subgroup comprises sequence encoding a peptide or polypeptide and/or a regulatory sequence; (ii) a plurality of peptides or polypeptides encoded by, or a plurality of regulatory sequences comprised within, each polynucleotide subgroup share an activity and/or function; (iii) at least one polynucleotide subgroup comprises at least two non-identical polynucleotide species; (iv) a plurality of polynucleotides of each polynucleotide subgroup comprises sequence enabling homologous recombination with a plurality of polynucleotides from one or more other polynucleotide subgroups; and (v) a plurality of polynucleotides in two polynucleotide subgroups comprise a nucleotideType: ApplicationFiled: November 23, 2012Publication date: October 9, 2014Inventors: Johannes Andries Roubos, Bernard Meijrink, Richard Kerkman, Ben Den Dulk
-
Publication number: 20140303103Abstract: The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using CAIX inhibitors.Type: ApplicationFiled: October 24, 2012Publication date: October 9, 2014Inventors: Paul C. McDonald, Frances E. Lock, Shoukat Dedhar
-
Publication number: 20140303231Abstract: The invention features therapeutic compositions comprising agents useful for the treatment or prevention of pruritis, and methods useful for identifying such agents.Type: ApplicationFiled: January 24, 2014Publication date: October 9, 2014Applicant: The Johns Hopkins UniversityInventors: Xinzhong Dong, Qin Liu, David J. Anderson
-
Publication number: 20140303035Abstract: The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.Type: ApplicationFiled: November 7, 2012Publication date: October 9, 2014Inventors: Sean Burns, David Altshuler, Amedeo Vetere
-
Patent number: 8852926Abstract: There is provided an expression cassette comprising a 3?-UTR cDNA library fragment, mammalian cells transfected with the expression cassette, and kits comprising the same. Furthermore, methods for identifying target genes for microRNAs are provided that utilize the expression cassette hereof.Type: GrantFiled: October 24, 2008Date of Patent: October 7, 2014Assignee: Board of Trustees of Southern Illinois UniversityInventors: Yin-Yuan Mo, Fangting Wu
-
Publication number: 20140296223Abstract: This invention relates to a method for regulating skin pigmentation of a subject, comprising the step of administering the agent for inhibiting the expression or activation of Microphthalmia Transcription Factor (MITF) to the subject who is in need of regulation of skin pigmentation.Type: ApplicationFiled: August 31, 2012Publication date: October 2, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: David E. Fisher, Rizwan Haq, Hans Ragnar Valdemar Widlund
-
Publication number: 20140294729Abstract: The invention relates to methods for identifying compounds and compositions that target cancer stem cells. In some aspects, the invention relates to treatment methods that use compounds and compositions that specifically target cancer stem cells for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof. Other aspects of the invention relate to the use of cancer stem cell biomarkers in the selection of a treatment for inhibiting the growth and/or survival of cancer stem cells in a subject in need thereof.Type: ApplicationFiled: October 28, 2013Publication date: October 2, 2014Applicants: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, President and Fellows of Harvard CollegeInventors: PIYUSH GUPTA, TAMER T. ONDER, ERIC S. LANDER, ROBERT A. WEINBERG, SENDURAI MANI, MAI-JING LIOA
-
Publication number: 20140296107Abstract: The present invention discloses a method of identifying agents that affect maturation and survival of oligodendrocytes or myelination of neuronal cells using ex-vivo differentiated embryonic stem cells.Type: ApplicationFiled: August 5, 2012Publication date: October 2, 2014Applicant: KADIMASTEM, LTD.Inventors: Michel Revel, Judith Chebath, Arye Hasson, Michal Izrael, Rosalia Kaufman
-
Publication number: 20140296106Abstract: The present invention relates to methods for screening substances capable of modulating the replication of an influenza virus.Type: ApplicationFiled: May 16, 2012Publication date: October 2, 2014Applicant: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Chantal Rabourdin-Combe, Lionel Tafforeau, Thibault Chantier, Anne Aublin-Gex
-
Publication number: 20140294855Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided is a method for repairing or regenerating a damaged muscle tissue of a subject.Type: ApplicationFiled: June 18, 2012Publication date: October 2, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Lee L. Rubin, Amanda Gee, Amy J. Wagers
-
Publication number: 20140287936Abstract: The small molecule profiles of cells are compared to identify small molecules which are modulated in altered states. Cellular small molecule libraries, methods of identifying tissue sources, methods for treating genetic and non-genetic diseases, and methods for predicting the efficacy of drugs are also discussed.Type: ApplicationFiled: December 13, 2013Publication date: September 25, 2014Applicants: CORNELL RESEARCH FOUNDATION, INC., METABOLON, INC.Inventors: Rima Kaddurah-Daouk, Bruce S. Kristal
-
Publication number: 20140275220Abstract: The present invention refers to inhibitors of microRNAs, particularly of microRNAs miR-212 and/or miR-132 for use in medicine, particularly in the diagnosis, treatment or prevention of cardiac disorders, e.g. cardiac hypertrophy-associated or autophagic disorders, and further refers to isolated nucleic acid molecules, particularly microRNAs miR-212 and/or miR-132 and related sequences, for use in medicine, particularly human medicine, more particularly in the diagnosis, treatment or prevention of disorders involving cardiac atrophy and/or dysfunctional autophagy, e.g. cardiac cachexia.Type: ApplicationFiled: September 6, 2012Publication date: September 18, 2014Applicants: Medizinische Hochschule Hannover, Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Thomas Thum, Kamal Chowdhury, Ahmet Ucar, Shashi Kumar Gupta
-
Publication number: 20140274796Abstract: The present invention comprises methods, systems and compositions comprising concentric chamber cell culture analog devices, comprising biologically functional cells, which function similarly to in vivo conditions.Type: ApplicationFiled: March 15, 2014Publication date: September 18, 2014Applicant: University of Central Florida Research Foundation, Inc.Inventor: James J. Hickman
-
Publication number: 20140274785Abstract: The invention disclosed herein describes a novel therapeutic target for motoneuron diseases (altered dynamics of microtubules and microtubule-mediated axonal transport of cargo molecules in neurons), with or without dementia, and in dementia; methods for measuring the state of activity of this therapeutic target in subjects with established, incipient, or potential motoneuron disease, with or without dementia, and in dementia; the discovery of drug agents that modulate neuronal microtubule dynamics in living subjects with motoneuron diseases; the discovery that administration of such agents, alone or in combinations, can improve MT-mediated transport of cargo molecules along and through axons; the discovery that such modulation of altered microtubule dynamics and improvement in MT-transport of molecules along axons can provide marked neuroprotective therapy for living subjects with motoneuron diseases, including delay in symptoms and prolongation of survival; and the discovery that monitoring of microtubule-mType: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Inventors: Marc Hellerstein, Patrizia Fanara
-
Publication number: 20140271488Abstract: Synthesis of compounds having varying degrees of conformational rigidity is obtained via a low cost, high yield and efficient synthetic reactions. The library of compounds is structurally diverse having at least one or more chiral centers and providing large numbers of compounds having building block diversity and substantial scaffold diversity. The compounds further provide a novel method for obtaining candidate therapeutic agents for prevention, treatment or diagnosis of diseases.Type: ApplicationFiled: September 7, 2012Publication date: September 18, 2014Applicant: The Scripps Research InstituteInventors: Glenn C. Micalizio, Thomas Kodadek, Mohosin Sarkar
-
Patent number: 8835360Abstract: A method for selecting combinations of drugs for treatment of diseases that arise from deranged signaling pathways is disclosed. The method involves measuring the activity states for signaling proteins in a diseased cell and determining whether the activity states are different from the activity states observed for a reference cell such as a normal cell. Based on the observed differences, combinations of two or more drugs are selected to reduce these differences. Treatment of a subject with the combinations restores the activity states of the signaling proteins of the deranged disease-associated signaling pathways toward the activity states observed in the reference cell. Since the diseased cell and the reference cell can both be obtained from the same subject, combinations of drugs that specifically target patient-specific signaling derangements is possible.Type: GrantFiled: April 24, 2012Date of Patent: September 16, 2014Assignee: The United States of America as represented by the Secretary of the Department of HHSInventors: Arpita I. Mehta, Lance A. Liotta, Emanuel F. Petricoin
-
Patent number: 8835399Abstract: Methods and constructs are provided for controlling processes in live animals, plants or microbes via genetically engineered near-infrared light-activated or light-inactivated proteins including chimeras including the photosensory modules of bacteriophytochromes and output modules that possess enzymatic activity and/or ability to bind to DMA, RNA, protein, or small molecules. DNA encoding these proteins are introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light of a different wavelength than the activating light. These proteins can regulate diverse cellular processes with high spatial and temporal precision, in a nontoxic manner, often using external light sources.Type: GrantFiled: July 27, 2012Date of Patent: September 16, 2014Assignee: University of WyomingInventors: Mark Gomelsky, Min-Hyung Ryu
-
Publication number: 20140256578Abstract: Methods and compositions for reducing expression of a mutant huntingtin (mHTT) protein in a cell are provided. Such methods include contacting the cell with an effective amount of a nucleic acid silencing agent targeting a differentiating polymorphism in RNA encoding the mHTT.Type: ApplicationFiled: February 6, 2014Publication date: September 11, 2014Applicant: The University of British ColumbiaInventors: Michael HAYDEN, Jeffrey CARROLL, Simon WARBY
-
Publication number: 20140256767Abstract: A method of identifying compounds as direct inhibitors of Keap1-Nrf2 interaction through high-throughput screening and lead development. The direct inhibitors of Keap1-Nrf2 interaction are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential drug candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, and Parkinson's. Novel compounds are identified and methods of preventing or treating diseases or conditions related to Keap1-Nrf2 interaction activity by use of the novel compounds identified or compositions containing such compounds are also disclosed.Type: ApplicationFiled: October 31, 2012Publication date: September 11, 2014Applicants: THE BROAD INSTITUTE, INC., RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Longqin Hu, Sadagopan Magesh, Lin Chen, Timothy Lewis, Ben Munoz, Lili Wang
-
Publication number: 20140259226Abstract: The present invention provides for compositions comprising mutated PYR/PYL receptor polypeptides that bind to a type 2 protein phosphatase in the absence of abscisic acid. The present invention further provides for methods of making and using the mutated PYR/PYL receptor polypeptides.Type: ApplicationFiled: June 19, 2012Publication date: September 11, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sean R. Cutler, Assaf Mosquna
-
Patent number: 8828680Abstract: In response to the need for highly-sensitive antibiotic susceptibility assays and identification assays that do not require extensive incubation times, the present invention provides automated assay methods and systems that permit the determination of antibiotic susceptibilities and/or microorganism identification in a timeframe that is substantially shorter than has previously been attainable using a hybrid system that combines turbimetric and fluorescence determinations using a single, clear-plastic assay platform. Related devices, kits, and components thereof are also disclosed.Type: GrantFiled: February 22, 2012Date of Patent: September 9, 2014Assignee: Siemens Healthcare Diagnostics Inc.Inventors: Gregory B. Williams, Daniel M. Nothaft, Glenn F. Enscoe, Kathleen N. Burtner, Monte E. Kangas
-
Patent number: 8828966Abstract: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in the retinal pigment epithelium (RPE) cells of the eye of the patient. Further, this method is achieved by modulating the action of the P2X7 and/or P2Y12 receptors of the RPE cells, specifically decreasing the acidity (pHL) of the RPE lysosomes by administering selected receptor antagonists affecting the action of the P2X7 and/or P2Y12 receptors of the RPE. Methods for selecting and quantifying the effectiveness of drugs to restore pHL and determine outer segment clearance rates is also provided using a high through-put screening protocol.Type: GrantFiled: April 27, 2012Date of Patent: September 9, 2014Inventors: Claire Mitchell, Alan Laties
-
Publication number: 20140248217Abstract: Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstuffs under specific conditions of production governed by xenohormetic effects.Type: ApplicationFiled: March 18, 2014Publication date: September 4, 2014Applicant: Palo Alto InvestorsInventor: Anthony Joonkyoo Yun
-
Publication number: 20140242658Abstract: The present invention is directed to variant squalene synthase enzymes, including Saccharomyces cerevisiae squalene synthase enzymes, and to nucleic acid molecules encoding these variant enzymes. These variant enzymes produce squalene at a lower rate than the wild-type enzyme, allowing more farnesyl pyrophosphate to be utilized for production of isoprenoid compounds, while still producing sufficient squalene to allow the S. cerevisiae cells to grow without the requirement for supplementation by sterols such as ergosterol. These variant enzymes, therefore, are highly suitable for the efficient production of isoprenoids.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Inventors: Bryan Julien, Richard Burlingame
-
Publication number: 20140243227Abstract: Culture media and methods for expanding and differentiating populations of stem cells and for obtaining organoids. Expanded cell populations and organoids obtainable by methods of the invention and their use in drug screening, toxicity assays and regenerative medicine.Type: ApplicationFiled: June 11, 2012Publication date: August 28, 2014Applicant: Koninklijke Nederlandse Akademie van WetenschappenInventors: Johannes C. Clevers, Toshiro Sato, Meritxell Huch Ortega, Wouter Richard
-
Patent number: 8815779Abstract: This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response.Type: GrantFiled: September 16, 2009Date of Patent: August 26, 2014Assignee: SwitchGear Genomics, Inc.Inventors: Shelley Force Aldred, Nathan D. Trinklein, Michael Rose, Patrick Collins
-
Patent number: 8815780Abstract: A method of immobilizing matter for imaging that includes providing an array of nanofibers and directing matter to the array of the nanofibers. The matter is immobilized when contacting at least three nanofibers of the array of nanofibers simultaneously. Adjacent nanofibers in the array of nanofibers may be separated by a pitch as great as 100 microns. The immobilized matter on the array of nanofibers may then be imaged. In some examples, the matter may be cell matter, such as protoplasts.Type: GrantFiled: February 9, 2012Date of Patent: August 26, 2014Assignee: UT-Battelle, LLCInventors: Timothy E. McKnight, Udaya C. Kalluri, Anatoli V. Melechko
-
Publication number: 20140234291Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: November 15, 2013Publication date: August 21, 2014Applicant: Celera CorporationInventors: Michele CARGILL, Ann B. BEGOVICH, Victoria CARLTON, Steven J. SCHRODI, Heather C. ALEXANDER
-
Publication number: 20140234902Abstract: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower eukaryotes, which ordinarily produce high-mannose containing N-glycans, including unicellular and multicellular fungi are modified to produce N-glycans such as Man5GlcNAc2 or other structures along human glycosylation pathways.Type: ApplicationFiled: May 7, 2014Publication date: August 21, 2014Applicant: GlycoFi, Inc.Inventor: Tillman U. Gerngross
-
Publication number: 20140234271Abstract: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that decrease p63 expression or activity or using the compounds described herein. The invention also features methods of using these compounds for increasing hair growth, improving skin health, or promoting skin repair in a subject.Type: ApplicationFiled: May 5, 2014Publication date: August 21, 2014Applicant: THE HOSPITAL FOR SICK CHILDRENInventors: Freda D. MILLER, David KAPLAN, Kristen SMITH, Maryline PARIS, Sibel NASKA
-
Publication number: 20140235498Abstract: Disclosed are methods for cell transfection and regulating cellular behavior. More particularly, the present disclosure relates to methods of non-viral cell transfection and regulating cellular behavior using mineral coatings that allow for the enhanced transfection of cells. The mineral coatings bind polynucleotides and provide a source of calcium and phosphate ions to enhance transfection. The present disclosure also provides a high throughput platform for screening non-viral transfection of cells. The methods of the present disclosure also provide an advantageous polynucleotide delivery platform because the mineral coatings may be deposited on various medical device materials after being specifically developed using the high throughput screening platform.Type: ApplicationFiled: February 19, 2013Publication date: August 21, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: William L. Murphy, Siyoung Choi, Xiaohua Yu
-
Publication number: 20140235499Abstract: An assay and system compatible with high throughput screening (HTS) that is capable of identifying inhibitors, such as small-molecule inhibitors, of the degradation of the Cdk inhibitor p21, are described. The assay is based on the use of fusion protein comprising (i) a p2 polypeptide; and (i) a reporter protein linked to the C-terminal of said p21 polypeptide, wherein the fusion protein has a half-life that is similar to that of the p21 polypeptide. Inhibitors identified by this assay may be useful to inhibit the proliferation of tumor cells, and thus for the treatment of cancers.Type: ApplicationFiled: September 28, 2012Publication date: August 21, 2014Inventors: Anne Marinier, Sylvain Meloche, Benoit Pelletier
-
Publication number: 20140235500Abstract: A system for the high-throughput screening of mechanical properties of cells and/or particles is provided. In certain embodiments the system comprises a first structure comprising a plurality of sample receiving wells; a second structure comprising a plurality of exit ports; a porous structure disposed between said plurality of sample receiving wells and said plurality of exit ports and in communication with said plurality of sample receiving wells and in communication with said plurality of exit ports, and said first structure, said second structure and said porous structure are sealed or configured such that when sufficient pressure is applied to sample receiving wells in said first structure said cells or particles migrate through the porous structure into said exit ports, and wherein the mean or the median pore size of said porous structure is smaller than the mean or median cross-section of a cell or particle that is to be screened.Type: ApplicationFiled: October 15, 2012Publication date: August 21, 2014Applicant: The Regents of the University of CaliforniaInventors: Amy Rowat, Dongping Qi
-
Publication number: 20140235468Abstract: The present invention provides an apparatus for conducting biological assays which employs “virtual wells” in lieu of the physical wells of conventional array plates. Also provided are methods of processing a sample and/or culturing cells using the apparatus and systems described herein. In some embodiments, the apparatus includes a first structure having a sheet layer with a plurality of discrete through holes; and a second structure coupled to the first structure, the second structure including a base layer. At least a portion of a first surface of the sheet layer of the first structure is exposed from the second structure, and a second surface of the sheet layer, opposite to the first surface of the sheet layer, is embedded in the base layer of the second structure adjacent the first surface of the base layer.Type: ApplicationFiled: October 9, 2013Publication date: August 21, 2014Applicant: Curiox Biosystems Pte Ltd.Inventors: Kong L. Cheng, Siah Chong Cheong, Namyong Kim, Eng Seng Kim, Melvin H.W. Lye, Zhong Wang, Wan Yee Leong, Mark S. Phong
-
Patent number: 8808999Abstract: The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.Type: GrantFiled: January 18, 2012Date of Patent: August 19, 2014Assignee: Pierre Fabre MedicamentInventors: Liliane Goetsch, Nathalie Corvaia, Alain Duflos, Jean-Francois Haeuw, Olivier Leger, Alain Beck
-
Publication number: 20140228248Abstract: The present invention provides, inter alia, methods for detecting whether a subject has an infection. These methods include (a) incubating a test sample from a subject suspected of having an infection with a labeled molecule, such as a labeled nucleoside analog, that is preferentially incorporated into a pathogenic microorganism for a period of time sufficient for the pathogenic microorganism to incorporate the labeled molecule; (b) removing any unincorporated labeled molecule from the test sample; and (c) detecting the labeled molecule within the pathogenic microorganism, if any, in the test sample, wherein the presence of labeled molecule within the pathogenic microorganism indicates that the subject has an infection.Type: ApplicationFiled: September 24, 2012Publication date: August 14, 2014Applicant: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh Saha, Chetan Bettegowda, David Tung